TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19470176

Group type: EXPERIMENTAL
Intervention: Aerobic and strength training program (3 weekly sessions for 8 weeks, 45-50 min each) focusing on muscular strength (leg press at 30% to 70% 1RM) and aerobic exercises (cycle-ergometry for 3-15 minutes at 12-14 RPE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (general physical activity guidelines)
Number of subjects: 60
Study: 17426181

Group type: EXPERIMENTAL
Intervention: Anti-D immune globulin (WinRho SDF), 50 microg/kg (250 IU/kg) intravenously
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 15478853

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic therapy
Number of subjects: 0
Study: 11092281

Group type: EXPERIMENTAL
Intervention: 15 mg pioglitazone
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: 45 mg pioglitazone
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 9091801

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg orally every 12 hours for five days)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 220
Study: 8371190

Group type: EXPERIMENTAL
Intervention: Topical APF gel (1.2% F‐) with daily use of placebo mouthrinse (Group B)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Fluoridated mouthrinse daily, ACT (0.05% F‐) (Group C)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo mouthrinse daily (Group A)
Number of subjects: 466
Study: 3079649

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (CT) 100 MRC units injected i.m. every other day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study: 31176287

Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude lumbar spinal manipulation (SMT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 80
Study: 30155761

Group type: EXPERIMENTAL
Intervention: Betalain-rich beetroot concentrate (BLN) 100 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 28
Study: 26405104

Group type: EXPERIMENTAL
Intervention: Training for trachoma grading (single day didactic training)
Number of subjects: 8
Study: 25493942

Group type: EXPERIMENTAL
Intervention: MNP + Fe (5 mg zinc, 12.5 mg iron)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MNP - Fe (5 mg zinc)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (placebo powder)
Number of subjects: 28
Study: 21621382

Group type: EXPERIMENTAL
Intervention: Tonsillectomy (TE) + adenoidectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) + adenoidectomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (before surgery)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (after surgery)
Number of subjects: 67
Study: 20040148

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling sessions and follow-up telephone calls
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 18339792

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) levels during acute exacerbation
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) levels in patients requiring ICU treatment
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BNP levels predicting the need for ICU care
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BNP levels predicting short-term mortality
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BNP levels predicting long-term mortality
Number of subjects: 208
Study: 15735109

Group type: EXPERIMENTAL
Intervention: Daily dose of iron (DI)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Daily dose of multiple micronutrients (DMM)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Weekly dose of multiple micronutrients
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 313
Study: 12889590

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (metronidazole plus erythromycin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 10617955

Group type: EXPERIMENTAL
Intervention: 30 mg elemental Zn/d
Number of subjects: 559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study: 8828534

Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone exposure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both air and ozone exposures
Number of subjects: 15
Study: 1425054

Group type: EXPERIMENTAL
Intervention: Diosmin (Daflon); 12 tablets in three divided doses for the first four days, then 2 tablets twice daily for another 10 days.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo; same regimen as diosmin.
Number of subjects: 100
Study: 3936108

Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms IV infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 30049236

Group type: EXPERIMENTAL
Intervention: Higher vegetable protein consumption
Number of subjects: 2413

Group type: COMPARATOR
Intervention: Animal protein and sugars consumption
Number of subjects: 2413
Study: 28915286

Group type: EXPERIMENTAL
Intervention: IVM+BR (Ivermectin 1% cream and Brimonidine 0.33% gel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVM+BR/12 weeks subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVM+BR/8 weeks subgroup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 25324277

Group type: EXPERIMENTAL
Intervention: Four-needle group (LI4, LI11, LI10, TE5)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Two-needle group (verum at LI4, LI11 and mock at LI10, TE5)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mock acupuncture group (LI4, LI11, LI10, TE5)
Number of subjects: 42
Study: 23663749

Group type: EXPERIMENTAL
Intervention: Advancing Recovery Framework (payer and treatment organization changes)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Treatment organization changes alone
Number of subjects: 175
Study: 21284066

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 19920051

Group type: EXPERIMENTAL
Intervention: Continuous-flow left ventricular assist device
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pulsatile-flow left ventricular assist device
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 200
Study: 17009635

Group type: EXPERIMENTAL
Intervention: Endometrial cancer group (EC)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study: 15656523

Group type: COMPARATOR
Intervention: Routine group (standard root canal therapy procedures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medicament group (dexamethasone tablets after instrumentation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drainage group (root canals prepared and left open for 2-3 days)
Number of subjects: 0
Study: 11134469

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 300 mg twice daily from 36 weeks' gestation until labor, then every 3 hours until delivery
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 9138438

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 7899000

Group type: EXPERIMENTAL
Intervention: Participants completed trials in front of an audience (treatment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Participants completed trials alone (control)
Number of subjects: 60
Study: 3116443

Group type: EXPERIMENTAL
Intervention: OKT3 (prophylactic use for 1 month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of azathioprine and OKT3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 0
Study: 2370758

Group type: EXPERIMENTAL
Intervention: Reaferon i.m. administration started on jaundice day 1-5 and lasted for 10-11 days
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Reaferon in delta infection
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Reaferon in fulminant hepatitis
Number of subjects: 412
Study: 31747093

Group type: EXPERIMENTAL
Intervention: Unpasteurised maternal milk (MM) intake (mL/kg/d)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Unpasteurised maternal milk (MM) intake (≥80%)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pasteurised donor milk (DM) intake
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Unpasteurised maternal milk (MM) intake
Number of subjects: 90
Study: 30739837

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with weekly cisplatin regimen
Number of subjects: 230

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 230
Study: 28641165

Group type: EXPERIMENTAL
Intervention: Common clinical definition of seizure clusters (≥3 seizures in a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel statistical definitions of seizure clusters (≥3 seizures in a day based on statistical exceedance of expected seizure rate)
Number of subjects: 0
Study: 25866383

Group type: EXPERIMENTAL
Intervention: MARKIT model for clinical trials management
Number of subjects: 0
Study: 23525425

Group type: EXPERIMENTAL
Intervention: Dynamic TIMI risk score for STEMI
Number of subjects: 0
Study: 21518585

Group type: EXPERIMENTAL
Intervention: TIVOLI biodegradable-polymer-based sirolimus-eluting stent
Number of subjects: 324

Group type: COMPARATOR
Intervention: ENDEAVOR zotarolimus-eluting stent
Number of subjects: 324
Study: 18991147

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline in a hydrogel
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16792559

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP) treatment before ethanol consumption
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment before ethanol ingestion
Number of subjects: 32
Study: 28933336

Group type: EXPERIMENTAL
Intervention: Oxycodone once-daily (OOD) 10 mg (oxycodone HCL 10-mg PR tablets XL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oxycodone twice-daily (OTD) 5 mg (oxygens 5-mg tablets)
Number of subjects: 36
Study: 11868856

Group type: EXPERIMENTAL
Intervention: Plasma Alpha‐2‐M levels in type 2 diabetic subjects with microalbuminuria
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasma Alpha‐2‐M levels
Number of subjects: 100
Study: 9562231

Group type: EXPERIMENTAL
Intervention: Aminoglycosides (specifically gentamicin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalosporins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined administration of cephalosporins and aminoglycosides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglycosides
Number of subjects: 0
Study: 7930234

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (80 ppm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nitroprusside (maximally tolerated dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 16
Study: 2465447

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study: 29386313

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27113960

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CNI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Difference in IMR change between EVR and CNI
Number of subjects: 70
Study: 25276763

Group type: EXPERIMENTAL
Intervention: IUD ML CU 375
Number of subjects: 48

Group type: COMPARATOR
Intervention: IUD Copper T 380A
Number of subjects: 48
Study: 23423269

Group type: COMPARATOR
Intervention: Continuous corticosteroid therapy (CCS)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal (CSWD)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: BCAR+BL
Number of subjects: 386
Study: 20607434

Group type: EXPERIMENTAL
Intervention: Promotora-led educational intervention
Number of subjects: 0
Study: 17728331

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) added to Methotrexate (MTX)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) added to Etanercept (ETN)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Combination therapy (ETN + MTX)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (previously receiving MTX or ETN monotherapy)
Number of subjects: 227
Study: 16887889

Group type: EXPERIMENTAL
Intervention: Concept mapping intervention
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Professionals' focus on positive aspects of medication
Number of subjects: 84
Study: 12746623

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) in non-insulin-treated type 2 DM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) in insulin-treated type 2 DM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured counseling educational programs for SMBG
Number of subjects: 0
Study: 11726257

Group type: EXPERIMENTAL
Intervention: Moderate Load (ML) - 13-15 repetitions with a moderate load on the chest press exercise, n = 16
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination Exercise (CX) - 6-8 repetitions with a heavy load on the chest press exercise immediately followed by 6-8 medicine ball chest passes, n = 12
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Heavy Load (HL) - 6-8 repetitions with a heavy load on the chest press exercise, n = 15
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Medicine Ball (MB) - 13-15 medicine ball chest passes, n = 11
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (CT) - Nontraining controls, n = 12
Number of subjects: 54
Study: 9222012

Group type: EXPERIMENTAL
Intervention: Fallopian tube epithelial cell co-culture
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional culture medium (Control)
Number of subjects: 91
Study: 7659824

Group type: EXPERIMENTAL
Intervention: Drainage withdrawn at 24 hours
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Drainage withdrawn at 72 hours
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Drainage withdrawn at 72 hours with previous vesical reeducation
Number of subjects: 106
Study: 2821052

Group type: EXPERIMENTAL
Intervention: Naloxone (10-mg iv bolus dose followed by an infusion of 30 micrograms/kg . h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 10
Study: 28081223

Group type: EXPERIMENTAL
Intervention: Jump training (JUMP) - 5-6 sessions per week consisting of 4x10 countermovement jumps and 2x10 hops in a sledge jump system.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CTRL) - no jump training.
Number of subjects: 23
Study: 25687667

Group type: EXPERIMENTAL
Intervention: Mindfulness training plus standard health education (HE-M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Attention-control intervention plus standard health education (HE-AC)
Number of subjects: 60
Study: 23355361

Group type: EXPERIMENTAL
Intervention: Single dose of ranolazine 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of ranolazine 1,000 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of ranolazine 1,500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple doses of ranolazine 500 mg twice daily for 7 days
Number of subjects: 12
Study: 21289042

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 439

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 439
Study: 19422663

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (combination of immunotherapy and chemotherapy); specific dosages and duration not available.
Number of subjects: 0
Study: 17350383

Group type: EXPERIMENTAL
Intervention: Anger provocation interview
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neutral interview
Number of subjects: 14
Study: 15478751

Group type: EXPERIMENTAL
Intervention: Ecological approach to data selection (contrast class account)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heuristic approach to data selection
Number of subjects: 50
Study: 11911409

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara-C) dose escalation to 15 and 20 mg/m2/d for 1-10 days
Number of subjects: 119
Study: 9840848

Group type: EXPERIMENTAL
Intervention: Ropivacaine at 4 mL/hour
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ropivacaine at 6 mL/hour
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ropivacaine at 8 mL/hour
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ropivacaine at 10 mL/hour
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 128
Study: 8030688

Group type: EXPERIMENTAL
Intervention: Continuous combined estradiol and norethindrone acetate (Kliogest)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sequential estradiol and norethindrone acetate (Trisequens)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 2913773

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 19
Study: 1176289

Group type: EXPERIMENTAL
Intervention: Kallikrein (a kinin-liberating proteinase) administered parenterally and orally over a period of seven weeks.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parenteral application of kallikrein.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kallikrein treatment.
Number of subjects: 30
Study: 29790405

Group type: EXPERIMENTAL
Intervention: Health education intervention during 6-month therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 27973678

Group type: EXPERIMENTAL
Intervention: Xbox KinectTM training for 20 sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Xbox KinectTM training
Number of subjects: 20
Study: 25414475

Group type: EXPERIMENTAL
Intervention: Benztropine (2 mg intramuscular)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 30
Study: 23911117

Group type: EXPERIMENTAL
Intervention: Visually demanding near work under four different trial-lens conditions
Number of subjects: 66
Study: 21903010

Group type: EXPERIMENTAL
Intervention: Body-weight-supported (BWS) ambulation on a fixed track (TRK)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Body-weight-supported (BWS) ambulation on a treadmill (TM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comprehensive physical therapy (PT)
Number of subjects: 35
Study: 19549678

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 175
Study: 16702572

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (administered to induce acute xerostomia in 10 men)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (administered to 10 men who served as controls)
Number of subjects: 20
Study: 14751424

Group type: EXPERIMENTAL
Intervention: risperidone 1‐12 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: haloperidol 2‐20 mg
Number of subjects: 41
Study: 11315533

Group type: EXPERIMENTAL
Intervention: CBT approach
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conjoint family therapy and eclectic approach
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up design
Number of subjects: 78
Study: 9452539

Group type: EXPERIMENTAL
Intervention: Intraoral lidocaine patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo patches
Number of subjects: 0
Study: 8950444

Group type: EXPERIMENTAL
Intervention: Simple ligation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ligation and inversion of the appendix stump
Number of subjects: 200
Study: 2124243

Group type: EXPERIMENTAL
Intervention: Interferon gamma (100 micrograms per subcutaneous injection, daily for the first 2 weeks, then 3 times per week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon gamma (100 micrograms per subcutaneous injection)
Number of subjects: 80
Study: 6996784

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine and triprolidine combination
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 31791405

Group type: EXPERIMENTAL
Intervention: Interactive tablet-based education intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control with no intervention
Number of subjects: 1200
Study: 27874185

Group type: EXPERIMENTAL
Intervention: Delirium-friendly preprinted postoperative orders (PPOs)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Routine postoperative orders
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Delirium-friendly PPOs
Number of subjects: 283
Study: 24921611

Group type: EXPERIMENTAL
Intervention: Basketball Plyometric Training (BPT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Basketball Technique Training (BTT)
Number of subjects: 36
Study: 24628966

Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 60

Group type: COMPARATOR
Intervention: White chocolate
Number of subjects: 60
Study: 22443058

Group type: EXPERIMENTAL
Intervention: Iron supplementation (8 mg daily of ferric pyrophosphate and ferrous fumarate)
Number of subjects: 74
Study: 20491957

Group type: EXPERIMENTAL
Intervention: PEGLip‐formulated FVIIa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard FVIIa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEGLip‐formulated FVIIa and Standard FVIIa
Number of subjects: 0